UNSPSC 51312609: Antazoline phosphate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H19N3.H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier VPR5FPH326, chemically known as 1h-imidazole-2-methanamine, 4,5-dihydro-n-phenyl-n-(phenylmethyl)-, phosphate (1:1) but more generally known as antazoline phosphate, which bears US NIH Compound Identifier 158798. European Medicines Agency schedules Antazoline phosphate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00541MIG.

UNSPSC 51312609 Antazoline phosphate is a Commodity code that encompasses prescription and over-the-counter pharmaceutical products supplied through state and local health, human services, and community health programs. Recent state and local solicitations under this code span naloxone procurement for emergency response and harm reduction, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals distributed through authorized wholesaler networks. State and local issuers procuring under the code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. Vendors must typically comply with cGMP certification, DSCSA compliance, FDA requirements, and E-Verify employment verification, with insurance requirements including commercial general liability and professional liability coverage in the $2 to $5 million range per occurrence.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, with responses due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, gathering market intelligence on direct contracting outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered through the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with pricing due March 26, 2026 and contract effectiveness targeted for July 1, 2026, requiring vendors to supply through AmerisourceBergen, Cardinal Health, and Morris & Dickson with evaluation weighted 75 percent on price competitiveness and 25 percent on administrative compliance, EDI capability, and manufacturing practice certification.